PL375211A1 - Sole farmaceutyczne reboksetyny - Google Patents

Sole farmaceutyczne reboksetyny

Info

Publication number: PL375211A1
Authority: PL; Poland
Prior art keywords: reboxetine; pharmaceutical salts; pharmaceutical; salts
Prior art date: 2002-06-17

Application number

PL03375211A

Other languages

English (en)

Inventor

Massimo Zampieri

Annalisa Airoldi

Alessandro Martini

Original Assignee

Pharmacia Italia S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-17

Filing date

2003-06-04

Publication date

2005-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL375211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-04 Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.

2005-11-28 Publication of PL375211A1 publication Critical patent/PL375211A1/pl

Links

CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical class CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title 1
229960003770 reboxetine Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL03375211A 2002-06-17 2003-06-04 Sole farmaceutyczne reboksetyny PL375211A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02077366		2002-06-17

Publications (1)

Publication Number	Publication Date
PL375211A1 true PL375211A1 (pl)	2005-11-28

Family

ID=29724495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03375211A PL375211A1 (pl)	2002-06-17	2003-06-04	Sole farmaceutyczne reboksetyny

Country Status (23)

Country	Link
US (2)	US20070010517A1 (pl)
EP (1)	EP1515959B1 (pl)
JP (1)	JP4563172B2 (pl)
KR (1)	KR100779786B1 (pl)
CN (2)	CN1662511B (pl)
AR (1)	AR040222A1 (pl)
AT (1)	ATE439354T1 (pl)
AU (1)	AU2003227755B2 (pl)
BR (1)	BR0311878A (pl)
CA (1)	CA2489763C (pl)
DE (1)	DE60328787D1 (pl)
DK (1)	DK1515959T3 (pl)
ES (1)	ES2328472T3 (pl)
MX (1)	MXPA04011916A (pl)
MY (1)	MY131231A (pl)
NO (1)	NO329346B1 (pl)
NZ (1)	NZ537023A (pl)
PE (1)	PE20040565A1 (pl)
PL (1)	PL375211A1 (pl)
RU (1)	RU2286341C2 (pl)
TW (1)	TWI267510B (pl)
WO (1)	WO2003106441A1 (pl)
ZA (1)	ZA200409624B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0319793D0 (en) *	2003-08-22	2003-09-24	Lilly Co Eli	Pyridinylmorpholine derivatives
WO2005082869A1 (en) *	2004-02-20	2005-09-09	Pharmacia & Upjohn Company Llc	Method for the preparation of aryl ethers
US8580776B2 (en) *	2007-07-10	2013-11-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) *	2008-09-06	2010-03-18	Bionevia Pharmaceuticals, Inc.	Novel forms of reboxetine
WO2018106825A1 (en) *	2016-12-06	2018-06-14	Tonix Pharmaceuticals Holding Corp.	Salts and polymorphs of esreboxetine
US12616702B2 (en)	2019-12-03	2026-05-05	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
US20260207613A1 (en) *	2025-01-21	2026-07-23	Axsome Therapeutics, Inc.	Pharmaceutical compositions comprising uniform blends of esreboxetine
US12565478B1 (en)	2025-01-21	2026-03-03	Axsome Therapeutics, Inc.	(S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2167407B (en) *	1984-11-22	1988-05-11	Erba Farmitalia	Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO1999015177A1 (en) *	1997-09-23	1999-04-01	Eli Lilly And Company	Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) *	1997-09-23	2003-05-15	Елі Ліллі Енд Компані	Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) *	1997-09-23	2003-06-16	Елі Ліллі Енд Компані	Спосіб лікування розладу поведінки
IT1305322B1 (it) *	1998-04-23	2001-05-04	Pharmacia & Upjohn Spa	Uso di reboxetina per il trattamento di disturbi nervosi
ATE305788T1 (de) *	1999-07-01	2005-10-15	Pharmacia & Upjohn Co Llc	(s,s)-reboxetin zur behandlung von inkontinenz

2003
- 2003-06-04 PL PL03375211A patent/PL375211A1/pl not_active Application Discontinuation
- 2003-06-04 AT AT03725195T patent/ATE439354T1/de not_active IP Right Cessation
- 2003-06-04 CA CA002489763A patent/CA2489763C/en not_active Expired - Fee Related
- 2003-06-04 WO PCT/EP2003/005261 patent/WO2003106441A1/en not_active Ceased
- 2003-06-04 JP JP2004513273A patent/JP4563172B2/ja not_active Expired - Fee Related
- 2003-06-04 CN CN038139839A patent/CN1662511B/zh not_active Expired - Fee Related
- 2003-06-04 BR BR0311878-9A patent/BR0311878A/pt not_active IP Right Cessation
- 2003-06-04 MX MXPA04011916A patent/MXPA04011916A/es active IP Right Grant
- 2003-06-04 CN CNA200810093308XA patent/CN101298440A/zh active Pending
- 2003-06-04 AU AU2003227755A patent/AU2003227755B2/en not_active Ceased
- 2003-06-04 KR KR1020047020412A patent/KR100779786B1/ko not_active Expired - Fee Related
- 2003-06-04 DE DE60328787T patent/DE60328787D1/de not_active Expired - Lifetime
- 2003-06-04 DK DK03725195T patent/DK1515959T3/da active
- 2003-06-04 ES ES03725195T patent/ES2328472T3/es not_active Expired - Lifetime
- 2003-06-04 NZ NZ537023A patent/NZ537023A/en unknown
- 2003-06-04 EP EP03725195A patent/EP1515959B1/en not_active Expired - Lifetime
- 2003-06-04 RU RU2005100846/04A patent/RU2286341C2/ru not_active IP Right Cessation
- 2003-06-04 US US10/588,808 patent/US20070010517A1/en not_active Abandoned
- 2003-06-11 TW TW092115889A patent/TWI267510B/zh not_active IP Right Cessation
- 2003-06-11 MY MYPI20032183A patent/MY131231A/en unknown
- 2003-06-13 AR ARP030102115A patent/AR040222A1/es unknown
- 2003-06-17 PE PE2003000594A patent/PE20040565A1/es not_active Application Discontinuation
2004
- 2004-11-29 ZA ZA200409624A patent/ZA200409624B/xx unknown
2005
- 2005-01-12 NO NO20050183A patent/NO329346B1/no not_active IP Right Cessation
2009
- 2009-05-21 US US12/469,780 patent/US20090291953A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2005100846A (ru)	2005-06-10
PE20040565A1 (es)	2004-09-02
CA2489763A1 (en)	2003-12-24
JP2005533791A (ja)	2005-11-10
DE60328787D1 (de)	2009-09-24
ATE439354T1 (de)	2009-08-15
NO329346B1 (no)	2010-10-04
EP1515959B1 (en)	2009-08-12
TWI267510B (en)	2006-12-01
DK1515959T3 (da)	2009-11-02
MY131231A (en)	2007-07-31
US20070010517A1 (en)	2007-01-11
NZ537023A (en)	2006-09-29
KR20050019137A (ko)	2005-02-28
JP4563172B2 (ja)	2010-10-13
CN1662511B (zh)	2010-06-09
CN1662511A (zh)	2005-08-31
NO20050183L (no)	2005-01-12
MXPA04011916A (es)	2005-03-31
US20090291953A1 (en)	2009-11-26
ZA200409624B (en)	2006-05-31
AR040222A1 (es)	2005-03-16
RU2286341C2 (ru)	2006-10-27
CA2489763C (en)	2007-12-18
HK1077572A1 (zh)	2006-02-17
BR0311878A (pt)	2005-04-05
TW200403230A (en)	2004-03-01
ES2328472T3 (es)	2009-11-13
KR100779786B1 (ko)	2007-11-28
EP1515959A1 (en)	2005-03-23
CN101298440A (zh)	2008-11-05
WO2003106441A1 (en)	2003-12-24
AU2003227755B2 (en)	2009-01-15
AU2003227755A1 (en)	2003-12-31

Legal Events

Date	Code	Title	Description
2010-12-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
SI1390023T1 (sl)	2008-10-31	Farmacevtske soli spojin 1-fenil-3-dimetilamino-propana
GB0217225D0 (en)	2002-09-04	Medicinal compounds
GB0225540D0 (en)	2002-12-11	Medicinal compounds
GB0204719D0 (en)	2002-04-17	Medicinal compounds
GB0225535D0 (en)	2002-12-11	Medicinal compounds
GB0220730D0 (en)	2002-10-16	Medicinal compounds
GB0225030D0 (en)	2002-12-04	Medicinal compounds
PL377495A1 (pl)	2006-02-06	Stały lek do stosowania doustnego
HRP20050429A2 (en)	2005-06-30	Dosage form of sodium ibuprofen
PL372773A1 (pl)	2005-08-08	Sposób podawania doustnego epotilonów
AU2003276572A1 (en)	2004-06-15	Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
GB0202900D0 (en)	2002-03-27	Novel formulations of drugs
IL166337A0 (en)	2006-01-16	Oral administration of calctionin
ZA200409624B (en)	2006-05-31	Pharmaceutical salts of reboxetine
GB0206505D0 (en)	2002-05-01	Pharmaceutical combination
AU2003295846A8 (en)	2004-06-18	Pharmaceutical formulations of celcoxib
PL373409A1 (pl)	2005-08-22	Kombinacja farmaceutyczna
GB0201520D0 (en)	2002-03-13	Pharmaceutical uses
PL355453A1 (pl)	2004-02-23	Środek farmaceutyczny
EP1491189A4 (en)	2007-08-08	ORAL PHARMACEUTICALS WITH DICLOFENAC SODIUM
GB0206708D0 (en)	2002-05-01	Pharmaceutical salts
GB0204683D0 (en)	2002-04-17	Pharmaceutical salts
GB0225702D0 (en)	2002-12-11	Oral formulation of moisutre-sensitive drugs
GB0220451D0 (en)	2002-10-09	Pharmaceutical use
HK1083584A (en)	2006-07-07	Pharmaceutical dosage forms of biguanide-sulfonylurea combinations